U.S. Markets close in 4 hrs 51 mins

What Analysts Think about Ionis

Mike Benson
What Analysts Think about Ionis

In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.